



American Academy  
of Value Based Care

# **AAVBC Medicare Part B IV/IM (Physician administered) to Part D SubQ (Patient self-administered) Utilization Quick Reference Guide**

2026

# AAVBV Medicare Part B IV/IM (Physician administered) to Part D SubQ (Patient self-administered) Guide

## Table of Contents

<b>1. INTRODUCTION: IV/IM &amp; SubQ ADMINISTRATION PRIMER.....</b>	<b>3</b>
Formulations and Bioequivalence.....	3
Equivalence and Dosing:.....	3
Immunogenicity and Long-Term Safety:.....	3
Quality of Life (QoL) and Patient Preference.....	4
Clinical efficacy and safety.....	4
Patient safety and administration barriers.....	4
Mitigation and support strategies.....	4
Regulations and Coverage.....	5
CMS Coverage Rules – Part B vs. Part D Determination.....	5
Self-Administered Drug (SAD) Exclusion List.....	5
Determining Coverage: Transitioning from Part B → Part D.....	6
Examples of Drugs Commonly Transitioning from Part B to Part D.....	7
<b>2. VALUE-BASED CARE &amp; OPERATIONAL STRATEGY.....</b>	<b>8</b>
VBC Incentives and Cost Savings.....	8
Patient Financial Impact – Part B vs. Part D.....	9
Operational Best Practices – Implementing A Part B → Part D Transition.....	10
Prior Authorization (PA) and Coverage Coordination.....	10
Patient Transition and Education.....	10
Specialty Pharmacy and Refill Management.....	10
Ongoing Monitoring and Follow-Up.....	11
<b>3. SUCCESS FACTORS.....</b>	<b>11</b>
Clear and Consistent Communication.....	11
Effective Transition Process.....	11
Proactive Stakeholder Management.....	12
Benefit and Formulary Strategy.....	12
<b>4. CONCLUSION.....</b>	<b>12</b>
<b>REFERENCES.....</b>	<b>13</b>

# 1. INTRODUCTION: IV/IM and SubQ ADMINISTRATION PRIMER

Value-Based Care (VBC) models encourage shifts in drug delivery that improve patient outcomes, benefit patient experience and reduce financial burden. One emerging strategy is transitioning eligible injectable medications from **Medicare Part B** (typically IV/IM infusions in clinics) to **Part D** (self-administered subcutaneous injections at home). This initiative hinges on recent advances that make self-injection feasible without sacrificing efficacy. When appropriate, patients can be empowered to self-administer medications, allowing providers to provide a more convenient patient experience while potentially reducing total medical spending. Below, we outline the clinical rationale, regulatory landscape, and operational tactics for a successful Part B-to-D drug transition program in a VBC framework.

## Formulations and Bioequivalence:<sup>1-3</sup>

High-concentration biologics face formulation challenges (e.g., viscosity, aggregation) that historically required IV administration, but new solutions are enabling subcutaneous (SubQ) administration. Manufacturers are using **viscosity-lowering excipients** and advanced device designs (autoinjectors, wearable pumps) to allow large doses in small volumes.

- **Overcoming Dose Volume Limits:** Historically, SubQ delivery was limited to small volumes (typically 1–2 mL), posing a challenge for high-dose biologic drugs. Newer technologies now enable the delivery of larger fluid volumes (often >3mL)<sup>1</sup>
- **Managing Viscosity and Concentration:** High drug concentration, often required for high doses, can increase **viscosity** and lead to formulation instability (e.g., aggregation). Manufacturers use excipients (such as salts and amino acids) and specialized formulation technologies to reduce viscosity<sup>1</sup>
- **Role of Hyaluronidase:** Many SubQ formulations are **co-formulated with recombinant human hyaluronidase (rHuPH20)**. Temporarily breaks down the hyaluronic acid barrier in subcutaneous tissue, allowing for the rapid dispersion and absorption of large-volume injections<sup>1</sup>

## Equivalence and Dosing:

- **Pharmacokinetic (PK) bridging studies** are the standard regulatory approach to confirm that the SubQ dose achieves drug exposure comparable to the approved IV form (non-inferiority)<sup>1-4</sup>
- Goal is for fixed-dose SubQ regimens to match the efficacy of weight-based IV dosing<sup>1,5</sup>
- **Clinical Vigilance:** Clinicians must be mindful that **flat SubQ dosing** (not based on weight) may risk under-dosing in patients at the extremes of body weight, necessitating monitoring and potential dose adjustment<sup>5</sup>

## Immunogenicity and Long-Term Safety:

The **route of administration** can affect how the immune system recognizes a drug, influencing long-term efficacy. However, in clinical practice, the **incidence of anti-drug antibodies (ADAs)** is generally **similar between subcutaneous (SubQ) and intravenous (IV) routes** for most biologics, and the theoretical increased immunogenicity with SubQ delivery **rarely leads to clinically significant differences** in safety or effectiveness.

- **Risk of Anti-Drug Antibodies (ADAs):** The subcutaneous space contains specialized antigen-presenting cells (APCs)
  - Since SubQ administration brings the drug directly into contact with these cells, there is a theoretical potential for an **enhanced immune response**, leading to the development of **Anti-Drug Antibodies (ADAs)**<sup>1,6</sup>
  - **Impact on Efficacy:** An ADA response can affect **the drug's pharmacokinetics and efficacy**, posing a significant clinical risk for long-term chronic therapy<sup>1,6</sup>
- **Current Evidence:** While some individual therapeutic proteins have shown a higher incidence of ADAs with SubQ administration, a comparison of 17 therapeutic proteins found **no statistically significant difference in ADA incidence between IV and SubQ routes overall**. The specific therapeutic protein itself, rather than the route, appears to be the most significant factor<sup>1</sup>

## Quality of Life (QoL) and Patient Preference<sup>7</sup>

- A 2024 meta-analysis of 30 studies found that **83% of adults with immune-mediated disorders** preferred **subcutaneous (SubQ)** administration over **intravenous (IV)** therapy, citing greater **convenience, flexibility, and autonomy**
- Patients reported **lower emotional distress** and **higher treatment satisfaction** with self-administered SubQ formulations, primarily due to reduced clinic time and greater control over scheduling
- Transitioning to home-based SubQ delivery has been associated with **improved adherence** and **reduced treatment fatigue** compared with traditional infusion-center models

## Clinical efficacy and safety<sup>7,8</sup>

- SubQ administration achieves **comparable efficacy and pharmacokinetics** to IV formulations across multiple biologic and immunoglobulin therapies
- **SubQ immunoglobulin (SubQIG)** produces **more stable serum IgG levels**, fewer systemic adverse effects (e.g., headaches, chills, fatigue), and **lower incidence of infusion reactions** than IVIG
- SubQ therapy allows for **smaller, more frequent doses**, improving physiologic tolerance and patient independence without compromising clinical outcomes

## Patient safety and administration barriers<sup>7</sup>

- Common issues include **incorrect storage, improper injection technique, site rotation errors**, and **sharps disposal** challenges
- Initial **self-injection anxiety** is frequent, especially among elderly or newly transitioned patients

## Mitigation and support strategies:

- Offer **nurse-led injection training** sessions and **first-dose supervision** (in person or virtual)
- Provide **step-by-step visual guides** and leverage **autoinjector pens** with safety locks to standardize technique
- Offer **pharmacist or nurse follow-up** within 1–2 weeks, along with **24-hour support lines** and **digital adherence tools** to reinforce technique and confidence

## Regulations and Coverage

When a drug is available in both **intravenous (IV)** and **subcutaneous (SubQ)** forms, its Medicare coverage, whether under Part B or Part D, is determined by whether it is considered “*usually self-administered*” by the patient. This classification is primarily influenced by the **route of administration** and CMS contractor determinations. Always confirm with MAC LCD and **review Medicare Benefit Policy Manual section 50.2 Determining Self-Administration of Drug or Biological**.

Increasingly, high-cost **Part B biologics** with SubQ alternatives are being transitioned to **Part D** when evidence supports equivalent safety and efficacy. These transitions enable **self-administration at home**, reduce total medical spend, and enhance **patient convenience and satisfaction** without compromising therapeutic outcomes.

Within **VBC** frameworks, physicians can support this shift by identifying eligible therapies and prescribing **SubQ formulations** when clinically appropriate to advance personalized, cost-effective care. Take steps to be up to date on recent transitions and coverage updates.

## CMS Coverage Rules – Part B vs. Part D Determination<sup>9</sup>

	Part B (Physician Administered)	Part D (Self-Administered)
<b>Definition</b>	Covers drugs administered <b>incident-to</b> a physician’s service; not usually self-administered	Covers drugs “ <b>usually self-administered</b> ” by the patient at home
<b>“Usually Self-Administered” 50% Rule</b>	Covered if <b>&lt;50%</b> of Medicare users self-administer	Excluded from Part B if <b>&gt;50%</b> of users self-administer → billed under Part D)
<b>Route of Administration Presumption</b>	<b>IV and IM</b> drugs are not self-administered (default Part B)	MACs maintain <b>Self-Administered Drug (SAD) Exclusion Lists</b> (revised periodically)
<b>Determining Authority</b>	<b>Medicare Administrative Contractors (MACs)</b> decide SAD classification and update coverage lists	MACs maintain <b>Self-Administered Drug (SAD) Exclusion Lists</b> (revised periodically)
<b>Clinical Implication</b>	Encourages <b>home-based self-administration</b> when safe and effective	Encourages <b>home-based self-administration</b> when safe and effective

## Self-Administered Drug (SAD) Exclusion List<sup>9</sup>

The SAD Exclusion List identifies medications that Medicare Part B will not cover because they are deemed “usually self-administered” by patients.

### [CMS Medicare SAD Exclusion List](#)

- Determining Authority:** Each Medicare Administrative Contractor (MAC) reviews drugs on a case-by-case basis as new utilization data and drug formulations become available. If **>50%** of Medicare users self-administer a drug, the MAC classifies it as a SAD and adds it to the exclusion list

- **Coverage Impact:** Drugs on this list are excluded from Part B reimbursement and must be billed under Part D *\*with exceptions\** (the outpatient prescription benefit)
- **Typical Drugs Affected:** Subcutaneous (SubQ) biologics, autoinjectors, or home-injectable therapies (e.g., abatacept, tocilizumab, SubQ immunoglobulin)
- Providers **cannot “buy and bill”** these drugs under Part B. Instead, prescriptions must be coordinated through a **Part D specialty pharmacy** for patient self-administration

## Determining Coverage: Transitioning from Part B → Part D<sup>9, 10</sup>

Determining Factor	Coverage Implication	Explanation/Examples
Route of Administration	IV/IM → Part B SubQ/SubQ → Part D	IV or IM drugs generally require clinician supervision and are Part B-covered. Subcutaneous (SubQ) drugs are presumed “usually self-administered” and move to Part D when >50% of beneficiaries self-administer.
Condition and Duration	Chronic → Part D Likely Acute → Part B Likely	Drugs for chronic maintenance (>2 weeks) are more likely to be self-administered. Example: long-term biologic therapy for autoimmune disease.
Frequency of Dosing	Less Frequent → Part D Likely Frequent/ Office-Based → Part B	Monthly or bi-monthly injections favor home use; frequent dosing needing monitoring stays under Part B.
CMS >50% Rule	If >50% self-administer → Excluded from Part B	CMS and its MACs classify any drug self-administered by most beneficiaries as SAD, removing it from Part B and listing it on the <a href="#">CMS Medicare SAD Exclusion List</a>
Clinical Principle		If a medication has both an in-office (IV/IM) and a home (SubQ) form, and the SubQ form > 50% self-administered, the SubQ form shifts to Part D. Determinations are made by MACs as new utilization data emerge

## Examples of Drugs Commonly Transitioning from Part B to Part D<sup>9</sup>

Drug (Generic/Brand)	Part B Version (Physician-Administered)	Part D Version (Patient Self-Administered)	Indication/Notes
<b>Prolia (Denosumab)</b>	SubQ injection administered by clinicians	SubQ self-administered at home	Osteoporosis; coverage depends on indication and site of administration
<b>Orencia (Abatacept)</b>	IV infusion	SubQ prefilled syringe /autoinjector	Rheumatoid arthritis; on SAD list since 2013
<b>Cimzia (Certolizumab)</b>	SubQ in-office injection	SubQ home self-administration	Crohn's disease, RA, PsA
<b>Nucala (Mepolizumab)</b>	SubQ by clinician	SubQ autoinjector for home use	Severe eosinophilic asthma
<b>Actemra (Tocilizumab) /Tyenne/Avtozma</b>	IV infusion	SubQ autoinjector or pen	Rheumatoid arthritis, Cytokine Release Syndrome; SubQ forms added to SAD list 2021
<b>Simponi Aria (Golimumab)</b>	IV infusion	Simponi® SubQ monthly autoinjector	RA, PsA; identical active ingredient, different benefit category
<b>Benlysta (Belimumab)</b>	IV infusion	SubQ autoinjector	Systemic Lupus Erythematosus
<b>Procrit/Retacrit (Epoetin alfa biosimilars)</b>	SubQ administered in office	SubQ self-administered	Anemia; switch improves adherence and reduces clinic visits
<b>Alemtuzumab</b>	IV induction therapy	SubQ formulation (transplant protocols)	Solid-organ transplant immunosuppression; MAC-reviewed case basis
<b>Immunoglobulin Therapy</b>	IVIG (clinic or home nursing)	SubQIG: Cuvitru®, Gamunex-C®, Hizentra®, HyQvia®	Replacement therapy for CVID, SubQID, CIDP – home administration reduces systemic AEs.
<b>Adalimumab (Humira®, Amjevita®)</b>	—	SubQ self-administered pen	Autoimmune conditions; long-standing SAD classification
<b>Secukinumab (Cosentyx®)</b>	—	SubQ self-administered	Psoriasis, PsA, AS
<b>Methotrexate (Otrexup®, Rasuvo®)</b>	SubQ/IM office injection	SubQ autoinjector	RA, Psoriasis; chronic use supports Part D classification
<b>Peginterferon beta-1a (Plegridy®)</b>	—	SubQ self-administered	Multiple Sclerosis
<b>Ustekinumab (Stelara®, Steqeyma®)</b>	IV induction (B)	SubQ maintenance (D)	Psoriasis, Crohn's disease
<b>Mirikizumab-mrkz (Omvoh®)</b>	IV induction	SubQ maintenance	Ulcerative Colitis

### Key Considerations:

- **Site of Administration:** The location and the person administering the drug are key factors. Part B covers drugs administered "incident to" a physician's service in a clinical setting. Part D covers drugs the patient gets from a pharmacy and takes themselves
- **Formulary Status:** The specific SubQ version must be on the patient's Part D plan's formulary (drug list) for coverage. If it's not, the patient may need to request a coverage exception

### Exceptions:<sup>10</sup>

CMS Publication 100-02, Chapter 15 (Covered Medical and Other Health Services), Section 50.2 (Drugs and Biologicals).

### The Five Key Statutory Exceptions

This CMS section explicitly details the categories of self-administered drugs (SADs) that must still be covered under Part B:

1. Certain Oral Anti-Cancer Drugs (if the IV form, covered under Part B)
2. Immunosuppressive Drugs (for patients who have received a Medicare-covered organ transplant)
3. Erythropoietin (EPO) (for certain home dialysis patients)
4. Blood Clotting Factors (for hemophilia patients)
5. Certain Osteoporosis Drugs (for limited homebound patients who meet specific criteria)

The existence of these exceptions is why, for the Part B-to-D transition, clinicians must **always check the indication** for the drug, **not just the route, to determine the correct payer.**

## 2. VALUE-BASED CARE AND OPERATIONAL STRATEGY

### VBC Incentives and Cost Savings

- **High-cost:**
  - Transitioning eligible biologics from Part B infusions to Part D self-administered subcutaneous (SubQ) forms can produce major system-level savings without compromising efficacy
- **Cost reduction:**
  - Economic models show **~\$18,000 annual savings per patient** when switching from IV to SubQ monoclonal antibody therapy<sup>11</sup>
  - Population-level analyses project **~\$3 billion in Medicare savings** over four years with 50% SubQ adoption among eligible patients<sup>11</sup>
- **Operational efficiencies:**
  - Frees up **infusion chair capacity** and reduces need for infusion staff and facility time
  - Cuts administrative load from scheduling, monitoring, and billing complexity under Part B
- **VBC alignment:**
  - Shifts spending from medical to pharmacy benefit, lowering total medical cost under shared savings and ACO models
  - Directly supports quality metrics and financial goals tied to cost containment and patient experience

## Patient Financial Impact – Part B vs. Part D<sup>12-15</sup>

Coverage Type	Out-of-Pocket Cost Structure	Typical Patient Scenario	Key Considerations (2025 and beyond)
<b>Part B (Medical Benefit)</b>	20% coinsurance per infusion (no annual limit)	\$5,000 infusion → \$1,000 patient coinsurance per visit	<ul style="list-style-type: none"> <li>Medicare supplement insurance often covers 100% of Part B coinsurance</li> <li>No annual out-of-pocket cap</li> <li>Patients without Medicare supplement insurance may face high recurring costs</li> </ul>
<b>Part D (Pharmacy Benefit)</b>	Copay or coinsurance varies by plan tier; subject to annual out-of-pocket cap	Drug filled at specialty pharmacy; paid monthly	<ul style="list-style-type: none"> <li><b>\$2,000 annual cap on out-of-pocket costs</b> effective in 2025, \$2100 in 2026</li> <li>Coinsurance based on formulary tier; varies by plan</li> <li>Out-of-pocket resets annually</li> </ul>
<b>Part D with Low-Income Subsidy (LIS/"Extra Help")</b>	Minimal or nominal cost-sharing	Average \$72/year for biologics vs. \$3,700+ for non-LIS patients	<ul style="list-style-type: none"> <li>Best protection for high-cost biologics</li> <li>Ideal for patients without supplemental Medigap coverage</li> <li>LIS significantly reduces cost exposure</li> </ul>
<b>Part D for Patients with Medicare supplement insurance</b>	Medicare supplement insurance <b>does not apply</b> to Part D	Previously paid \$0 under Part B; now may owe up to \$2,000 annually	<ul style="list-style-type: none"> <li>Providers should counsel patients on cost shift</li> <li>Manufacturer copay cards not allowed; use <b>charitable or foundation-based assistance</b></li> </ul>

The transition from Part B to Part D changes how patients pay for their medications. Under Part B, patients owe 20% coinsurance per infusion, though most with Medicare supplement insurance pay little or nothing. When the same drug moves to Part D, Medicare supplement insurance no longer applies, and patients face copays or coinsurance through their pharmacy plan. However, **2025 reforms cap annual Part D out-of-pocket costs at \$2,000, offering protection that Part B lacks.**<sup>12, 13</sup>

Those with the Low-Income Subsidy (LIS) pay the least, often under \$100 per year, while beneficiaries with Medicare supplement insurance may now owe modest costs they did not previously see. In short, Part D can lower expenses for patients without Medicare supplement insurance or with LIS but may increase costs slightly for others, making proactive financial counseling and benefits review essential before transition.

## Operational Best Practices – Implementing A Part B → Part D Transition

*“Don’t let the patient go it alone.”*

### 1. Prior Authorization (PA) and Coverage Coordination

Action Step	Best Practice Guidance
<b>Initiate PA Early</b>	Submit PA <b>before transition</b> to avoid treatment gaps. Include patient diagnosis, prior therapy history, and rationale for switching (e.g., “stable on IV form; converting to SubQ for home use”)
<b>Use ePA Portals</b>	File PAs through <b>electronic prior authorization (ePA)</b> systems to expedite processing and track status
<b>Formulary Exceptions</b>	If the plan prefers a biosimilar or IV/IM alternative, submit a <b>formulary exception request</b> for SubQ formulation supported by clinical documentation and rationale.
<b>Coordinate With Specialty Pharmacy</b>	Maintain open communication with the <b>Part D specialty pharmacy</b> to confirm PA approval, drug shipment, and delivery timing

### 2. Patient Transition and Education

Action Step	Best Practice Guidance
<b>Designate a Care Lead</b>	Assign an <b>RN or clinical pharmacist</b> to oversee each patient’s transition from IV to SubQ therapy
<b>Provide Injection Training</b>	Conduct or arrange <b>hands-on or virtual education sessions</b> on injection technique, storage, site rotation, and sharps disposal
<b>Supply Written &amp; Visual Aids</b>	Give patients <b>easy-to-follow instructions</b> and troubleshooting guides for home reference
<b>Schedule First-Dose Support</b>	Offer <b>first-injection observation</b> (in-person or virtual) to ensure proper administration and patient confidence

### 3. Specialty Pharmacy and Refill Management

Action Step	Best Practice Guidance
<b>Enroll in Mail-Order Programs</b>	Use <b>manufacturer or plan-supported mail-order options</b> for reliable, temperature-controlled home delivery
<b>Verify Refill Scheduling</b>	Ensure patients understand <b>refill timelines</b> and how to request replacements to avoid therapy lapses
<b>Monitor for Delays</b>	Proactively track shipping and refill requests; address barriers promptly through plan liaison or case management

## 4. Ongoing Monitoring and Follow-Up

Action Step	Best Practice Guidance
<b>Short-Term Follow-Up</b>	Conduct a <b>1–2 week post-switch call or visit</b> to assess adherence, injection comfort, and early adverse effects
<b>Long-Term Monitoring</b>	Integrate <b>patient-reported outcomes (PROs)</b> and adherence tracking into follow-up visits or digital health tools
<b>Document Progress</b>	Capture improvements in convenience, QoL, and adherence for internal VBC reporting
<b>Continuous Support</b>	Encourage patients to use <b>manufacturer nurse lines or tele-support</b> if they experience difficulties

## Success Factors

### 1. Clear and Consistent Communication

Audience	Focus Area	Guidance
<b>Patients</b>	Cost and access education	Provide clear information on new coverage pathways, potential cost differences (Medicare Supp Insurance vs. LIS), and steps to obtain medications under Part D. Include written materials + helpline support
<b>Providers</b>	Clinical workflow updates	Ensure prescribers understand updated coverage rules, authorization processes, and documentation requirements to prevent therapy delays.
<b>Health Plans</b>	Member transition assistance	Maintain transparent outreach from <b>Part D sponsors</b> to guide beneficiaries on switching to covered drugs or submitting formulary exception requests

### 2. Effective Transition Process

Goal	Best Practice
<b>Ensure Timely Access</b>	Prevent coverage gaps by confirming authorization and dispensing pathways before transition. Pharmacy counter delays must be proactively avoided
<b>Use Grace Periods</b>	Apply <b>CMS-approved transition periods (e.g., 90 days)</b> to allow time for education and coverage alignment
<b>Streamline Exceptions</b>	Standardize formulary exception and appeal workflows for rapid turnaround; prioritize cases with urgent medical need

### 3. Proactive Stakeholder Management

Audience	Engagement Focus	Implementation Tip
Patients and Caregivers	Financial and access variability	Identify those at risk for increased costs (e.g., Medicare Supplement Insurance holders) and provide proactive counseling
Advocacy Organizations	Equity and safety	Collaborate with patient advocacy groups to ensure safe self-administration and equitable access for vulnerable populations
Pharmacies/Home Infusion Providers	Supply chain coordination	Maintain communication for home delivery, training logistics, and refill tracking to prevent treatment interruptions

### 4. Benefit and Formulary Strategy

Objective	Operational Focus
Use Regulatory Flexibility	Apply MTM and risk-stratification programs to support adherence and manage costs under VBC models
Optimize Formularies	Meet CMS minimum standards ( $\geq 2$ drugs per class) while avoiding unnecessary utilization barriers (e.g., redundant prior auths). Protectively scan for SubQ formulations to add to the health plan formulary
Continuous Monitoring	Evaluate adherence, patient satisfaction, and cost outcomes quarterly; refine plan design based on real-world performance

## Conclusion

Transitioning eligible Part B drugs to Part D self-administration is a promising strategy at the intersection of clinical innovation and value-based care. It leverages pharmacological advances (SubQ formulations with hyaluronidase) to maintain efficacy and safety while substantially improving the patient experience. From a policy perspective, Medicare is clearly defining which drugs belong under Part D, and forward-thinking practices are adapting by identifying patients who can benefit from home therapy.

The potential rewards are significant: patients gain convenience and autonomy, payers and providers see reduced costs, and infusion capacity is freed up for those who truly need in-clinic care. However, success requires careful execution, appropriate patient selection, proactive navigation of Part D rules, and intensive patient education are all critical. When done thoughtfully, Part B-to-D drug transitions can exemplify high-value care: achieving the same or better health outcomes at a lower cost and with higher patient satisfaction.

As Medicare and healthcare systems continue to push for **“the right care at the right place,”** the shift of injectable therapies into the home setting will likely expand, making the strategies outlined above increasingly essential in routine practice.

---

## REFERENCES

1. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. *AAPS J.* 2018;20(6):100. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6182494/>. Accessed 2025.
2. Pharmacokinetics-Based Design of Subcutaneous Controlled Release Systems for Biologics. *J Pharm Sci.* 2025;114(1):21-36. <https://pmc.ncbi.nlm.nih.gov/articles/PMC12001277/>. Accessed 2025.
3. Mijangos LRR, Harding SE, Darton NJ. Developing high-concentration monoclonal antibody formulations for subcutaneous administration to improve patient treatment. *Biophys Rev.* 2025;17(3):571-583. <https://doi.org/10.1007/s12551-025-01346-2>. Accessed 2025.
4. Koenitz L, Crean A, Vucen S. Pharmacokinetic differences between subcutaneous injection and intradermal microneedle delivery of protein therapeutics. *Eur J Pharm Biopharm.* 2024;204:114517. doi:10.1016/j.ejpb.2024.114517.
5. Erstad BL, Barletta JF. Implications of obesity for drug administration and absorption from subcutaneous and intramuscular injections: A primer. *Am J Health-Syst Pharm.* 2022;79(15):1236-1244. doi:10.1093/ajhp/zxac058.
6. Felderman J, Ramaiah L, Vazquez-Abad MD, Messing D, Chen Y. Anti-Drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route. *AAPS J.* 2024;26(3):60. doi:10.1208/s12248-024-00930-w.
7. Bril V, Lampe J, Cooper N, Kiessling P, Gardulf A. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis. *J Comp Eff Res.* 2024;13(9):e230171. doi:10.57264/ceer-2023-0171.
8. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. *J Allergy Clin Immunol.* 2017;139(3):S1-S46. doi:10.1016/j.jaci.2016.09.023.
9. Centers for Medicare & Medicaid Services. Article A52800: Self-Administered Drug Exclusion List. Updated June 1, 2025. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=52800>. Accessed 2025.
10. Centers for Medicare & Medicaid Services. Drugs and Biologicals. In: *Medicare Benefit Policy Manual.* Pub 100-02. Chap 15, Sec 50.2. Updated periodically. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>. Accessed 2025.
11. Tahami Monfared AA, Barrows S, Fox L, et al. Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer's Disease: A U.S. Cost Comparison Model. *Neurol Ther.* 2025;14(5):1863-1888. doi:10.1007/s40120-025-00790-2.
12. Cubanski J, Neuman T. How the Inflation Reduction Act will affect Medicare beneficiaries' drug costs. KFF website. Published January 31, 2024. Accessed 2025. <https://www.kff.org/medicare/explaining-the-prescription-drug-provisions-in-the-inflation-reduction-act/#bullet03>
13. Centers for Medicare & Medicaid Services. Medicare Part D Redesign under the Inflation Reduction Act: Summary of Key Provisions. Updated July 2024. <https://www.cms.gov/newsroom/fact-sheets/final-cy-2026-part-d-redesign-program-instructions>. Accessed 2025.
14. Centers for Medicare & Medicaid Services. Low-Income Subsidy (LIS) Program – Extra Help with Medicare Prescription Drug Plan Costs. Updated March 2025. <https://www.cms.gov/medicare/enrollment-renewal/part-d-plans/low-income-subsidy>. Accessed 2025.
15. DiStefano MJ, Kang S, Parasrampur S, Anderson GF. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance. *JAMA Health Forum.* 2023;4(5):e231090. doi:10.1001/jamahealthforum.2023.1090

## Medical Disclaimer

The information provided by the American Academy of Value-Based Care (AAVBC) in this document, including but not limited to utilization management guidance, and related content, is intended for educational and informational purposes only. This content is designed to assist healthcare providers, organizations, and professionals in understanding and applying Value-Based Care principles, practices, and regulatory compliance standards.

AAVBC does not provide legal, clinical, or medical advice. The content presented should not be interpreted or relied upon as specific legal, medical, clinical, or professional guidance. While efforts are made to ensure the accuracy and currency of the information provided, AAVBC does not guarantee that the materials presented are complete, comprehensive, or without error.

Providers and healthcare professionals must independently evaluate all content and guidance presented herein in the context of applicable laws, regulations, clinical guidelines, payer policies, patient-specific conditions, and contraindications. Any treatments, procedures, diagnostic approaches, medications, or strategies discussed are illustrative and should not be directly applied without a thorough and independent review of current, evidence-based clinical resources, and regulatory requirements.

For coding, documentation, utilization management, quality measures (including STAR ratings), and compliance matters, users are responsible for consulting official guidelines issued by regulatory bodies, including but not limited to the Centers for Medicare & Medicaid Services (CMS), the American Medical Association (AMA), relevant state agencies, and other authoritative entities.

AAVBC expressly disclaims liability for any loss, claim, or damages arising directly or indirectly from the use or reliance on information provided in this document. Users should consult their organization's legal counsel, compliance officer, or qualified professional advisor for advice specific to their situation.

By accessing and using this document, you agree to AAVBC's terms and acknowledge that the use of the content is at your own risk and discretion.